התחייבויות שוטפות של החברה: Evolus Inc (EOLS)

Historical price action for Evolus, Inc. (EOLS) on the GURU.Markets platform demonstrates the impact of high business scalability focused on high-demand botulinum toxin, which minimizes development costs. Growth is supported by the expansion of aesthetic neurotoxins, which are actively displacing older analogs among younger demographics. The current short-term debt metric stands at 0.00, confirming the company's resilience within the healthcare sector.

Evolus, Inc. (EOLS) is actively scaling its digital platform and expanding the clinical indications for Jeuveau. Such capital-intensive R&D investments directly impact the structure of current liabilities. This indicator aggregates all debts maturing within one year to assess the risk of a liquidity gap. A decrease in this metric may signal either financial recovery or a reduction in expansion. Analyze the total amount of short-term debt to monitor operational liquidity.